The event is over. See you in the next one.
About this event
Bright Minds Chief Medical Officer, Dr. Revati Shreeniwas and Bright Minds collaborator and world renown addiction researcher Dr. Kathy Cunningham of University of Texas Medical Branch will be discussing the findings of our pre-clinical trial evaluating the efficacy of our 5-HT2c program to treat Opioid Use Disorder in a brief 10 minute webinar.
Hosted by
We are a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases.